Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: NUMIF )

0.0800 +0.0023 (+2.96%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about NUMIF

< Previous 1 2 3 4 5 6 7 8 9 Next >
GH Research, Numinus Wellness Among Top Psychedelic Movers Of Today
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 3.03% at $0.85 
Via Benzinga
Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 3.12% at $0.82 
Via Benzinga
Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 29.44% at $0.56 
Via Benzinga
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 6.63% at $0.71 
Via Benzinga
Numinus to Acquire Novamind For $20.74M In Stock
Via Benzinga
Numinus To Provide Psychedelic-Assisted Therapy In This Western State
The mental health care company Numinus Wellness Inc. 
Via Benzinga
Psychedelic Stock Gainers And Losers From June 22, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 4.17% at $3.50 
Via Benzinga
Numinus Submits New Patent Application To UN Agency For Psilocybe & Novel Fungi Species
Numinus Wellness Inc. 
Via Benzinga
Revive Therapeutics, Numinus Wellness Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 7.43% at $0.31 
Via Benzinga
Psychedelic Stock Gainers And Losers From June 17, 2022
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 5.69% at $0.67 
Via Benzinga
Michael Pollan's 'How To Change Your Mind' Coming Soon To Netflix: Documentary Based On Psychedelics Best Seller
The freshest news traversing many of the major institutions, researchers' and activists’ accounts on Twitter is the recent release of a docu-series based on writer Michael Pollan’s 2018 book “How To... 
Via Benzinga
Psychedelic Stock Gainers And Losers From June 16, 2022
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.08% at $10.05 LOSERS: 
Via Benzinga
Psychedelic Stock Gainers And Losers From June 15, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 9.11% at $0.62 
Via Benzinga
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. 
Via Benzinga
Psychedelic Stock Gainers And Losers From June 14, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 9.90% at $9.44 
Via Benzinga
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 1.06% at $0.81 LOSERS: 
Via Benzinga
Only One Cannabis Stock Category Is Up So Far In June
The cannabis sector consists of 5 distinct categories and they have each performed quite differently so far in June and YTD; 4 are down in June and all have dropped substantially YTD. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From June 10, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 6.16% at $0.67 
Via Benzinga
New Acquisition: Novamind To Buy Common Shares Of Numinus Pending Canadian Supreme Court Approval
Numinus Wellness Inc. 
Via Benzinga
Numinus' Ongoing Collaboration With Health Canada Spurs Mindspace Clinic Approval In Quebec
A longstanding commitment of Numinus Wellness Inc. (OTC: NUMIF) to collaborate with Health Canada to help shape protocols for the Special Access Program appears to be paying dividends. 
Via Benzinga
3 of 5 Cannabis Categories Declined During Third Week Of May
The cannabis sector consists of 5 distinct categories and they each performed quite differently from each other during the third week of May. 
Via Talk Markets
Psyched: Compass, Atai And MindMed Release Q1 Earnings, Phase 3 MDMA Trial Closer To Completion, Enveric Splits Into Two Companies
The psychedelics space got a new glimpse at the financials of some of its heavy hitters with the release of earnings reports for the first quarter of 2022. 
Via Benzinga
Numinus Granted Canada's Special Access Program For Magic Mushrooms To Treat Life-Threatening Conditions
Numinus Wellness Inc (OTCQB: NUMIF) has been approved to use psilocybin-assisted therapy through Health Canada’s Special Access Program (SAP), marking the first instance in which Numinus will provide... 
Via Benzinga
2 Of The 5 Cannabis Categories Advanced Slightly During Second Week Of May
The cannabis sector consists of 5 distinct categories, each performing differently from the other. Here, the stock performances during the second week of May, YTD and from the 2021 peak. 
Via Talk Markets
Novamind And Numinus Prepare For Acquisition, Both Companies Share Info Circulars To Shareholders
June 8, 2022 marks a turning point for both Numinus (OTCQX: NUMIF) and Novamind (OTCQB: NVMDF). 
Via Benzinga
Novamind To Offer Virtual Mental Health Therapy Sessions
Novamind (OTCQB: NVMDF), which is to be acquired by Numinus Wellness (OTCMKTS: NUMIF), recently announced a collaboration with health coaching platform HealCommunit 
Via Benzinga
Numinus Wellness Strives To Become Psychedelic Research Hub After Acquisition Of Novamind Inc.
In a year where M&A activity is expected to ratchet-up in 2022, Numinus Wellness Inc. (OTC: NUMIF) is among the first to take action. 
Via Benzinga
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector. 
Via Benzinga
March Update: Psychedelic Compounds-Based Drug Stocks Index Went Down -19%
An update on the revisions that have been made to the Pure-Play Psychedelic Compounds-Based Drug Stocks Index with the increase in the minimum market capitalization required to be included in the... 
Via Talk Markets
Numinus Administers MDMA To First Volunteer In Clinical Trial Sponsored By MAPS
Numinus Wellness Inc. (OTCQX: NUMIF), announced that clinical trial MAPPUSX has gotten underwaywith the enrolling and dosing ... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.